Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

2617d866-0750-4a93-a533-5e15b536bfa9

—

9a6d4db0-4c46-592a-b3f6-9519a8de5c3e

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • E2F_TARGETS+0.400
  • G2M_CHECKPOINT+0.400
  • MYC_TARGETS_V1+0.400
  • ANDROGEN_RESPONSE+0.300
  • MITOTIC_SPINDLE+0.300
  • MTORC1_SIGNALING+0.300
  • MYC_TARGETS_V2+0.300
  • PROTEIN_SECRETION+0.300
  • PI3K_AKT_MTOR_SIGNALING+0.200
  • SPERMATOGENESIS+0.200

Top 10 suppressed

  • ANGIOGENESIS-0.400
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
  • INTERFERON_ALPHA_RESPONSE-0.400
  • COAGULATION-0.300
  • INTERFERON_GAMMA_RESPONSE-0.300
  • MYOGENESIS-0.300
  • APICAL_JUNCTION-0.200
  • CHOLESTEROL_HOMEOSTASIS-0.200
  • ALLOGRAFT_REJECTION-0.100
  • APOPTOSIS-0.100

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-33-4538-01A-01R-1201-07
lung-landscapes@6
—cohortSQ20.857
2SRR1313140
breast-umap@18
—E0.847
3MDT-AP-2085
medullo-epn-umap@date-based
MedMedulloblastoma0.835
4SRR26320071
bladder-landscape@3
——0.834
5TCGA-A2-A25E-01A-11R-A169-07
breast-umap@18
—B0.828
657ab4aef-e740-4494-b0b5-3b008f9d446f
melanoma-umap@29
——0.827
7TCGA-GC-A4ZW-01A-11R-A26T-07
bladder-landscape@3
——0.827
8R143
bladder-landscape@3
——0.822
9MDT-AP-2956
medullo-epn-umap@date-based
MedMedulloblastoma0.810
10MDT-AP-2497
medullo-epn-umap@date-based
MedMedulloblastoma0.809

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 20 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
E2F_TARGETS0.400Inavolisib— uncovered
G2M_CHECKPOINT0.400Inavolisib— uncovered
MYC_TARGETS_V10.400Inavolisib— uncovered
ANDROGEN_RESPONSE0.300Inavolisib— uncovered
MITOTIC_SPINDLE0.300Inavolisib— uncovered
MTORC1_SIGNALING0.300Inavolisib— uncovered
MYC_TARGETS_V20.300Idelalisib— uncovered
PROTEIN_SECRETION0.300Remibrutinib— uncovered
PI3K_AKT_MTOR_SIGNALING0.200Inavolisib— uncovered
SPERMATOGENESIS0.200Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.200Idelalisib— uncovered
ADIPOGENESIS0.100Inavolisib— uncovered
FATTY_ACID_METABOLISM0.100Inavolisib— uncovered
HEME_METABOLISM0.100Temsirolimus— uncovered
NOTCH_SIGNALING0.100Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.100Remibrutinib— uncovered
PEROXISOME0.100Idelalisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.100Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.100Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.100Inavolisib— uncovered